| First Author | Spinosa MD | Year | 2021 |
| Journal | Am J Pathol | PubMed ID | 34509440 |
| Mgi Jnum | J:312953 | Mgi Id | MGI:6792408 |
| Doi | 10.1016/j.ajpath.2021.08.012 | Citation | Spinosa MD, et al. (2021) B Cell-Activating Factor Antagonism Attenuates the Growth of Experimental Abdominal Aortic Aneurysm. Am J Pathol |
| abstractText | B cell-activating factor (BAFF), a tumor necrosis factor family of cytokine, was recently identified as a regulator of atherosclerosis; however, its role in aortic aneurysm has not been determined. Here, we examined the effect of selective BAFF antagonism using an anti-BAFF antibody (blocks binding of BAFF to receptors BAFF receptor 3, transmembrane activator and CAML interactor, and B-cell maturation antigen) and mBaffR-mFc (blocks binding of BAFF to BAFF receptor 3) on a murine model of abdominal aortic aneurysm (AAA). In a prevention strategy, the antagonists were injected before the induction of AAA, and in an intervention strategy, the antagonists were injected after the induction of AAA. Both strategies attenuated the formation of AAA. In the intervention group, BAFF antagonism depleted most of the mature B-cell subsets in spleen and circulation, leading to enhanced resolution of inflammation in AAA as indicated by decreased infiltration of B cells and proinflammatory macrophages and a reduced number of apoptotic cells. In AAA tissues, B cells and macrophages were found in close contact. In vitro, B cells, irrespective of treatment with BAFF, impaired the efferocytosis activity of macrophages, suggesting a direct innate role of B cells on macrophage function. Altogether, BAFF antagonism affects survival of the mature B cells, promotes resolution of inflammation in the aorta, and attenuates the growth of AAA in mice. |
